BioCentury
ARTICLE | Clinical News

XAF5: Phase II data

March 9, 2015 7:00 AM UTC

A double-blind, U.S. Phase II trial in about 90 patients with excess eyelid fat showed that once-daily topical XA45 for 10 weeks met the primary endpoint of a greater proportion of patients achieving ...